SAN DIEGO, July 12, 2012 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") announced today that it has completed clinical enrollment with the ReZolve® drug-eluting bioresorbable scaffold. A total of 26 patients have been enrolled and there are no major adverse coronary events ("MACE") reported to date. The first patient in the study was enrolled in December 2011. REVA plans to provide an update on data from these patients at the Transcatheter Cardiovascular Therapeutics (TCT) 2012 Conference, which will be held in October in Miami, Florida.
